Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin R Farlow

Showing results (31-40 of 189) with videos related to

Pageof 19
Sort By:
Drugs & Aging|December 21, 2013
Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging InitiativeNoam U Epstein, Rong Guo, Martin R Farlow, et al.
Clinical Drug Investigation|December 10, 2009
Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's diseaseJeffrey L Cummings, Martin R Farlow, Xiangyi Meng, et al.
Journal of Alzheimer'S Disease : JAD|April 21, 2020
A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's DiseaseSamuel T Henderson, Bruce H Morimoto, Jeffrey L Cummings, et al.
American Journal of Alzheimer'S Disease and Other Dementias|September 20, 2015
Quality Improvement in Skilled Nursing Facilities for Residents With Alzheimer's DiseaseMartin R Farlow, Soo Borson, Stephen R Connor, et al.
Dementia and Geriatric Cognitive Disorders Extra|November 1, 2013
Comparing clinical profiles in Alzheimer's disease and Parkinson's disease dementiaMartin R Farlow, Frederick Schmitt, Dag Aarsland, et al.
Dementia and Geriatric Cognitive Disorders|May 27, 2010
Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysisJeffrey L Cummings, Steven H Ferris, Martin R Farlow, et al.
Drugs & Aging|July 28, 2010
Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristicsNoam U Epstein, Andrew J Saykin, Shannon L Risacher, et al.
Alzheimer Disease and Associated Disorders|December 2, 2014
A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer DiseaseMartin R Farlow, George T Grossberg, Carl H Sadowsky, et al.
CNS Neuroscience & Therapeutics|February 14, 2015
Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's DiseaseMartin R Farlow, Carl H Sadowsky, Drew M Velting, et al.
Dementia and Geriatric Cognitive Disorders|May 11, 2012
Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantineRachelle S Doody, David S Geldmacher, Martin R Farlow, et al.
Pageof 19

Showing results (31-40 of 189) with videos related to

Sort By:
Pageof 19
Drugs & Aging|December 21, 2013
Medication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging InitiativeNoam U Epstein, Rong Guo, Martin R Farlow, et al.
Clinical Drug Investigation|December 10, 2009
Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's diseaseJeffrey L Cummings, Martin R Farlow, Xiangyi Meng, et al.
Journal of Alzheimer'S Disease : JAD|April 21, 2020
A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's DiseaseSamuel T Henderson, Bruce H Morimoto, Jeffrey L Cummings, et al.
American Journal of Alzheimer'S Disease and Other Dementias|September 20, 2015
Quality Improvement in Skilled Nursing Facilities for Residents With Alzheimer's DiseaseMartin R Farlow, Soo Borson, Stephen R Connor, et al.
Dementia and Geriatric Cognitive Disorders Extra|November 1, 2013
Comparing clinical profiles in Alzheimer's disease and Parkinson's disease dementiaMartin R Farlow, Frederick Schmitt, Dag Aarsland, et al.
Dementia and Geriatric Cognitive Disorders|May 27, 2010
Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysisJeffrey L Cummings, Steven H Ferris, Martin R Farlow, et al.
Drugs & Aging|July 28, 2010
Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristicsNoam U Epstein, Andrew J Saykin, Shannon L Risacher, et al.
Alzheimer Disease and Associated Disorders|December 2, 2014
A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer DiseaseMartin R Farlow, George T Grossberg, Carl H Sadowsky, et al.
CNS Neuroscience & Therapeutics|February 14, 2015
Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's DiseaseMartin R Farlow, Carl H Sadowsky, Drew M Velting, et al.
Dementia and Geriatric Cognitive Disorders|May 11, 2012
Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantineRachelle S Doody, David S Geldmacher, Martin R Farlow, et al.
Pageof 19